Navigation Links
HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China
Date:12/15/2008

Collaboration will leverage HUYA's growing Chinese bioscience network

SAN DIEGO, Dec. 15 /PRNewswire/ -- HUYA Bioscience International, a leader in US/China pharmaceutical co-development, today announced an agreement with Schering-Plough Corporation's subsidiary, N.V. Organon. Schering-Plough has selected HUYA to identify and present to Schering-Plough on an exclusive basis proprietary lead, preclinical and clinical drug candidates in specific therapeutic areas that originate in China.

"HUYA is quickly gaining a reputation as a key point of contact for members of the Chinese bioscience community looking to establish relationships with Western development partners," said Mirielle Gingras, PhD, President and CEO of HUYA. "Our agreement with Schering-Plough demonstrates both the effectiveness of our network in China, and our ability to leverage that network to benefit major development partners in the West. We are delighted to be forging this new alliance, and look forward to a fruitful collaboration."

Schering-Plough will gain access to HUYA's growing Chinese bioscience network comprising premier universities, government research institutions and bioparks throughout the country. HUYA already has agreements in place with several of these organizations whereby HUYA has ongoing exclusive access to compounds and biologics in a variety of indications. The company is currently evaluating and following the progress of more than 500 drug development candidates.

HUYA's model is based on longevity of relationships with its Chinese partners to provide a continuous source of compounds rather than a one-time single compound strategy. The ongoing exchange of expertise and data is intended to lower risk and facilitate rapid and efficient clinical development in both China and the West.

HUYA currently has two Chinese drugs undergoing preclinical development in the US - HBI-3000 and HBI-8000. Both drugs, for cardiac fibrillation and oncology, respectively, have successfully passed US FDA pre-IND consultations.

HUYA's Innovative Co-Development Model

HUYA was one of the first companies to recognize China's potential to help meet the global need for pre-clinical and clinical stage compounds for the drug development process. Leveraging the HUYA Integrated Co-development Model for partnering with Chinese research institutions and pharmaceutical companies, HUYA identifies and licenses highly promising pre-clinical and clinical stage compounds in China. HUYA's Chinese partners retain development and marketing rights in China with the expectation that both parties will benefit from the research and development collaboration.

One of the key differentiators of HUYA's approach HUYA is the assembly of a high-level team of scientific and clinical advisors for each new compound. The team collaborates with its' Chinese partners to discuss and design clinical trials as the compounds enter the U.S. development process, speeding the process and mitigating risk. HUYA's global team of advisors includes Benedict Lucchesi, MD, PhD, Peter R. Kowey, MD, Dennis Roy, MD, Jefferson L. Anderson, MD, Eric J. Topol, MD, Stanley Nattel, MD, Anthony Tolcher, MD, Alex Adjei, MD, PhD, Patricia LoRusso, DO and Michael Robertson, MD.

"From my involvement with the cardiac fibrillation program, I have been impressed with the relationship that HUYA has forged with its Chinese partners," said Eric Topol, MD, Chief Academic Officer, Scripps Health, San Diego, CA. "HUYA's co-development model is an excellent system for developing new drugs and ultimately introducing them into the Western market."

About HUYA

HUYA is a leader in U.S./China pharmaceutical co-development with three strategic offices in China, a broad Chinese compound portfolio, and a significant number of exclusive agreements with premier Chinese biotech centers. HUYA has joint headquarter offices in San Diego, CA, and Shanghai. Additional information about the company is available at www.huyabio.com.

    Contact:

    USA:
    Jan Tuttleman, PhD
    Vice President, Marketing
    HUYA Bioscience International, LLC
    (858) 798-8800
    jtuttleman@huyabio.com

    China:
    Ben Ni, PhD
    Head of Therapeutics
    HUYA Bioscience International, LLC
    86 (21) 51323312
    bni@huyabio.com

    Media Contacts:

    Amy Berry
    (415) 793-2258
    amyeberry@comcast.net

    Juliet Travis
    (510) 452-3771
    juliet@travispr.com


'/>"/>
SOURCE HUYA Bioscience International
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pressure BioSciences, Inc. and Omni International Announce Marketing, Distribution, and Technology Development Agreement
2. YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE
3. CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East
4. DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product
5. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
6. Frost & Sullivan Recognizes Martek Biosciences for Unique and Customer-Focused Strategies With Customer Value Enhancement Award
7. PURE Bioscience and Ciba Strike New Contract for Natural Antimicrobial
8. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
9. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
10. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
11. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... phase I/II dose escalation and expansion clinical trial for its lead drug candidate, ... The purpose of the trial was to determine the safety, antitumor activity, and ...
(Date:12/7/2016)... Dec. 7, 2016 Neogen Corporation (NASDAQ: ... Dan Kephart as its chief science officer ... assume his responsibilities at Neogen effective Jan. 1. ... for the agribusiness unit of Thermo Fisher Scientific, as ... Life Technologies. His extensive industry experience also includes the ...
(Date:12/7/2016)... OTTAWA, Ontario , Dec. 7, 2016 /PRNewswire/ ... partnership with General Atomics (GA), welcome today,s award ... National Nuclear Security Administration (NNSA) of the Phase ... its project with Nordion and the University of ... Phase II funding will support the establishment of ...
Breaking Biology Technology:
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/16/2016)... SAN FRANCISCO , June 16, 2016 /PRNewswire/ ... Market size is expected to reach USD ... report by Grand View Research, Inc. Technological proliferation ... and banking applications are expected to drive the ... ) , The development of ...
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
Breaking Biology News(10 mins):